Candlestick · Volume · EMA · BB · VWAP · MACD · RSI · Drawing Tools
Candlestick chart with volume — data via Yahoo Finance · For educational use only
$2 Billion Bayer Verdict: What the Roundup Decision Means for MAHA
By Exec Edge Editorial Staff When a Georgia jury ordered Bayer to pay $2.1 billion to a single plaintiff in March 2025, the verdict sent shockwaves through both the pesticide industry and the MAHA movement. The award—$65 million in compensatory damages and $2 billion in punitive damages—was the largest single-plaintiff verdict in Georgia history. For […]
CollectiveMinds LLC, a leading next-generation executive search firm specializing in life sciences and biotechnology, today announced the successful placement of Robert Hollingsworth, PhD, as Chief Scientific Officer of Protillion Biosciences, Inc. Protillion is an innovative, venture-backed biotechnology company headquartered in Carlsbad, California, backed by ARCH Venture Partners and Illumina Ventures.
Which S&P500 stocks are the most active on Tuesday?
Stay informed about the most active stocks in the S&P500 index on Tuesday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
How Ireland became dependent on big pharma — and the risks ahead
In just 50 years, Ireland has become the world’s third largest exporter of pharmaceuticals, with medicines now making up about 20% of Ireland’s GDP. So how did Ireland become so tied to the pharma industry — and is that reliance at risk amid tariffs, patent cliffs and geopolitical tension?
Dallas, TX, March 31, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse report, “The Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity Medicine.” The report provides a comprehensive analysis of the rapidly evolving amylin drug landscape, a mechanism once considered commercially unviable that is now at the center of global pharmaceutical strategy. Over the past eighteen months, more than $19 billion in deal valu
Sentiment scored by an AI model on article tone. Not investment advice.
Trade risk-free with $10,000 virtual cash.
Paper trading only — no real money involved
Open a real trading account with a regulated broker:
View Broker Options →Pfizer (PFE) is currently trading at live market price. See the live chart on this page for the latest move. Prices update live throughout market hours on this page.
Wall Street analyst consensus, AI signals, and recent news sentiment for PFE are shown above. StockifyX surfaces the data; the decision is yours — try the call risk-free with paper trading first.
The next PFE earnings date is shown in the Earnings section above, along with the historical EPS surprise track record.
Dividend yield, payout ratio, and ex-dividend date for PFE are listed in the Dividends card on this page when applicable.
StockifyX gives you $10,000 in virtual cash to paper-trade PFE at real market prices — no real money required. Click "Paper Trade" above to get started.
The latest PFE headlines with sentiment scoring, plus the full Wall Street analyst rating breakdown, are listed further down this page.